Skip to main navigation
Skip to search
Skip to main content
Northwestern Scholars Home
Help & FAQ
Home
Experts
Organizations
Research Output
Grants
Core Facilities
Research Data
Search by expertise, name or affiliation
Clinical trials of β-blockers in heart failure: A class review
Clyde W. Yancy
*
*
Corresponding author for this work
Medicine, Cardiology Division
Research output
:
Contribution to journal
›
Review article
›
peer-review
10
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Clinical trials of β-blockers in heart failure: A class review'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Angiotensin-converting Enzyme Inhibitor (ACEi)
33%
Beta-blockers
100%
Clinical Trials
100%
Disease Progression
33%
Heart Failure
100%
Heart Failure Trials
33%
High Risk
33%
Hospitalization
33%
Illness
33%
Improved Patient Outcomes
33%
Increased Incidence
33%
Increasing Prevalence
33%
Left Ventricular Dysfunction
33%
Mortality Risk
33%
Neurohormonal Response
33%
Ongoing Trials
33%
Patients with Heart Failure
33%
Reduced Mortality
33%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Congestive Heart Failure
100%
Dipeptidyl Carboxypeptidase Inhibitor
20%
Disease
20%
Disease Exacerbation
20%
Heart Left Ventricle Failure
20%
Prevalence
20%
Nursing and Health Professions
Congestive Heart Failure
100%
Dipeptidyl Carboxypeptidase Inhibitor
20%
Disease
20%
Disease Exacerbation
20%
Heart Left Ventricle Failure
20%
Prevalence
20%
Treatment Outcome
20%